| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (NCT05361668) | Crinetics Pharmaceuticals Inc. | 2022-04-22 |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease (NCT05064514) | Queen Mary University of London | 2022-04-06 |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NCT04713202) | Chandrikha Chandrasekhara | 2021-03-03 |
| Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome (NCT04776876) | M.D. Anderson Cancer Center | 2021-03-01 |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy (NCT04039516) | King's College Hospital NHS Trust | 2020-10-01 |
| Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency (NCT04073017) | Vanderbilt-Ingram Cancer Center | 2019-11-04 |
| Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs (NCT03722511) | Lowell Anthony, MD | 2018-12-06 |
| AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm (NCT03453489) | Barbara Ann Karmanos Cancer Institute | 2018-06-20 |
| Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO (NCT03223428) | TerSera Therapeutics LLC | 2017-06-22 |
| Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation (NCT04140409) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2016-02-02 |
| Telotristat Etiprate for Carcinoid Syndrome Therapy (NCT02063659) | Lexicon Pharmaceuticals | 2014-03-11 |
| Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms (NCT02026063) | Lexicon Pharmaceuticals | 2014-01-14 |
| An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males (NCT01932528) | Lexicon Pharmaceuticals | 2013-08-01 |
| Study of Panitumumab in the Treatment of Carcinoid Syndrome (NCT01172717) | Boston Medical Center | 2013-07-01 |
| TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) (NCT01677910) | Lexicon Pharmaceuticals | 2013-01-08 |
| Effects of Serotonin Excess on Bone in Carcinoid Syndrome (NCT01430871) | Sheffield Teaching Hospitals NHS Foundation Trust | 2011-01-01 |
| A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea (NCT01234168) | Ipsen | 2010-10-01 |
| Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome (NCT01104415) | Lexicon Pharmaceuticals | 2010-06-15 |
| Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (NCT01018953) | Ipsen | 2010-02-01 |
| Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome (NCT00884715) | Endo USA Inc., a Keenova Therapeutics Company | 2009-07-01 |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (NCT00774930) | Ipsen | 2009-05-01 |